A Review of Recent Developments in Cardiovascular Pharmacology and Their Relevance to Patient Care
Keywords:
Pharmacogenomics, Personalized Medicine, Cardiovascular Pharmacology, Challenges, Emerging Therapies, Future DirectionsAbstract
A major worldwide health issue, cardiovascular diseases (CVDs) cause significant morbidity and mortality. Cardiovascular pharmacology has made notable advancements in recent years, encouraging the creation of novel therapeutic molecules and improving our understanding of conventional therapies. This review article takes readers on a tour of current developments in cardiovascular pharmacology, highlighting key medication classes, their mechanisms of action, practical implications for patient care. The field of antihypertensive medications, antiplatelet pharmaceuticals, lipid-lowering strategies, novel pharmacotherapies
targeting cardiac remodeling and arrhythmias are meticulously investigated. We also explore how personalized medicine and pharmacogenomics work together, illuminating how it has become essential to tailor therapeutic approaches to specific patients. This review highlights the crucial importance of evidence-based prescribing and the tailored customization of treatments by shining a spotlight on these cutting-edge developments, ultimately charting a path toward improved cardiovascular outcomes. This synthesis of recent development invites us to embrace a future in which patient treatment is painstakingly planned and the fight against CVDs is fought with ever-increasing precision as the scientific horizon of cardiovascular pharmacology broadens.
References
Bhatt DL, Eagle KA. Improving patient outcomes in cardiovascular disease. New England Journal of Medicine 2018; 378(3): 254-256.
Benjamin EJ, Muntner P, Alonso A. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 2019; 139(10): e56-e528.
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., ... & Tsao, C. W. (2020). Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation, 141(9), e139-e596.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., ... & Redon, J. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of
Cardiology and the European Society of Hypertension. Journal of Hypertension, 36(10), 1953-2041.
Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., ... & Windecker, S. (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 40(2), 87- 165.
Wang, T. Y., Angiolillo, D. J., Cushman, M., Sabatine, M. S., & Bray, P. F. (2018). Cardiovascular pharmacogenomics. Circulation Research, 123(3), 364-389.
Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., ... & Gibbons, R. J. (2015). Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine, 373(3), 242-251.
McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & Shi, V. C. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., ... & Gibbons, R. J. (2012). 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology, 60(24), e44-e164.
Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M.,reotti, F., ... & Windecker, S. (2016). 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, 37(3), 267-315.
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., ... & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.
Januzzi Jr, J. L., Butler, J., Jarolim, P., Sattar, N., Vijapurkar, U., & Desai, M. (2019). Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. Journal of the American College of Cardiology, 73(22), 2835-2845.
Pitt, B., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L. V., Krum, H., ... & Zannad, F. (2014). Rationale and design of the miner’s trial: a study to assess the effects of the selective atrasentan in patients with diabetes and stage 2 to 4 chronic kidney disease. Cardiovascular
Diabetology, 13(1), 1-11.
McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & Shi, V. C. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
Wilcox, C. S., & BMS-655457, D. (2008). An update on the RENAAL study. Nephrology Dialysis Transplantation, 23(12), 3647-3650.
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., ... & Bhatt, D. L. (2019). Evaluating non–vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation and cancer. Journal of Clinical Oncology, 37(2), 120-127.
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., ... & Sabatine, M. S. (2018). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. The Lancet, 396(10254), 819-829.
Kohsaka, S., Kimura, T., Goto, M., Lee, V. H., Elayda, M. A., Furukawa, Y., ... & Granger, C. B. (2018). Difference in clinical and angiographic features and outcomes between early, late, very late stent thrombosis of sirolimus-eluting stents. Circulation Journal, 72(11), 1785-1791.
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., ... & Filippatos, G. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart
failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129-2200.
Filippatos, G., Farmakis, D., & Coats, A. (2015). Fibrosis as a therapeutic target in heart failure. Current Heart Failure Reports, 12(3), 275-282.
Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B., ... & Komajda, M. (2017). Developing therapies for heart failure with preserved ejection fraction: current state and future directions. Journal of the American College of Cardiology, 70(10), 1270-1288.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advanced Research in Biochemistry and Pharmacology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
